

INTROGEN THERAPEUTICS INC

Form 8-K

August 26, 2004

**Table of Contents**

---

---

**SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 26, 2004 (August 24, 2004)**

**Introgen Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction  
of incorporation)

0-21291  
(Commission  
File Number)

74-2704230  
(IRS Employer  
Identification No.)

301 Congress Avenue, Suite 1850, Austin, Texas  
(Address of principal executive offices)

78701  
(Zip Code)

Registrant's telephone number, including area code: (512) 708-9310

(Former name or former address, if changed since last report)

---

---

---

**TABLE OF CONTENTS**

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Item 9.01. Financial Statements and Exhibits.

**INDEX OF EXHIBITS**

Press Release

---

**Table of Contents**

**Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.**

Effective August 24, 2004, Mahendra G. Shah, Ph.D. resigned from the Board of Directors of Introgen Therapeutics, Inc. (the Company). Dr. Shah had served as a director of the Company since the Company's inception in 1993. Also on August 24, 2004, Peter Barton Hutt was appointed to the Company's Board of Directors to fill the vacancy created by Dr. Shah's resignation. The Company issued a press release on August 24, 2004 regarding this matter, which is filed as Exhibit 99.1 to this Current Report on Form 8-K. The contents of such Exhibit are incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits.

99.1 Press Release dated August 24, 2004.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 26, 2004

INTROGEN THERAPEUTICS, INC.

/s/ James W. Albrecht, Jr.  
James W. Albrecht, Jr.  
Chief Financial Officer

-2-

---

**Table of Contents**

INDEX OF EXHIBITS

<b>Exhibit Number</b>	<b>Description of Document</b>
99.1	Press Release dated August 24, 2004.